Clinical trials
Observational Heart Arrest trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
27 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2012 | 3 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 3 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 13 |
| Completed | 6 |
| Recruiting | 5 |
| Not yet recruiting | 2 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Capital Medical University | 4 |
| Beijing Anzhen Hospital | 2 |
| Peking Union Medical College Hospital | 2 |
| Shanghai 10th People's Hospital | 2 |
| Tang Ziren | 2 |
| Beijing Tiantan Hospital | 1 |
| Central China Fuwai Hospital of Zhengzhou University | 1 |
| Chinese PLA General Hospital | 1 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| First Affiliated Hospital, Sun Yat-Sen University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Heart Arrest | 27 |
| Brain Injuries | 4 |
| Heart Failure | 4 |
| Shock, Cardiogenic | 4 |
| Death, Sudden, Cardiac | 2 |
| Respiratory Distress Syndrome | 2 |
| Acute Kidney Injury | 1 |
| Angina, Unstable | 1 |
| Aortic Diseases | 1 |
| Arrhythmias, Cardiac | 1 |
Trials
Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.